A case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: A case report

被引:4
作者
DeBiasio, Celina [1 ]
Cyr, Janelle [2 ]
Ayroud, Yasmine [3 ]
Glassman, Steven J. [2 ]
机构
[1] Univ Ottawa, Fac Med, Ottawa, ON, Canada
[2] Univ Ottawa, Dept Med, Div Dermatol, 4th Floor Civ Parkdale Clin,737 Parkdale Ave, Ottawa, ON K1Y 1J8, Canada
[3] Univ Ottawa, Dept Anat Pathol & Lab Med, Ottawa, ON, Canada
关键词
Pityriasis rubra pilaris; systemic therapy; skin diseases; papulosquamous;
D O I
10.1177/2050313X221093453
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Classic adult pityriasis rubra pilaris is a severe papulosquamous disease that tends to resolve in 3-5 years but can have a devastating impact on patients while active. It shares features with psoriasis, but treatment remains largely empiric, based on case reports and series. The condition is often refractory to treatment, especially initially, with topical corticosteroids and oral acitretin the more commonly employed agents. Relatively high doses of acitretin are needed for adequate response, and adverse events often limit adherence. Given the similarity to psoriasis, biologic agents approved for psoriasis have been used with good effect in classic adult pityriasis rubra pilaris and show better tolerance than other agents. In this report, we describe the successful use of a combination of acitretin and ustekinumab in a case of classic adult pityriasis rubra pilaris.
引用
收藏
页数:4
相关论文
共 16 条
[1]  
Bonomo L, 2018, CUTIS, V101, P367
[2]   Successful response of refractory type I adult-onset pityriasis rubra pilaris with ustekinumab and acitretin combination therapy [J].
Byekova, Yevgeniya ;
Sami, Naveed .
JOURNAL OF DERMATOLOGY, 2015, 42 (08) :830-831
[3]   Ustekinumab as an Alternative Treatment Option for Chronic Pityriasis Rubra Pilaris [J].
Chowdhary, Mudit ;
Davila, Ulysses ;
Cohen, David J. .
CASE REPORTS IN DERMATOLOGY, 2015, 7 (01) :46-50
[4]   Treatment of pityriasis rubra pilaris type I: a systematic review [J].
Engelmann, Carina ;
Elsner, Peter ;
Miguel, Diana .
EUROPEAN JOURNAL OF DERMATOLOGY, 2019, 29 (05) :524-537
[5]   Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris [J].
Feldmeyer, Laurence ;
Mylonas, Alessio ;
Demaria, Olivier ;
Mennella, Anna ;
Yawalkar, Nikhil ;
Laffitte, Emmanuel ;
Hohl, Daniel ;
Gilliet, Michel ;
Conrad, Curdin .
JAMA DERMATOLOGY, 2017, 153 (04) :304-308
[6]  
Ghosh S, 2019, DRUG SAFETY, V42, P751, DOI 10.1007/s40264-019-00797-3
[7]   Pityriasis Rubra Pilaris A Review of Diagnosis and Treatment [J].
Klein, Annette ;
Landthaler, Michael ;
Karrer, Sigrid .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2010, 11 (03) :157-170
[8]   Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation [J].
Maloney, Nolan J. ;
Hisaw, Lisa D. ;
Worswick, Scott .
DERMATOLOGIC THERAPY, 2017, 30 (06)
[9]   Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review [J].
Naidoo, Avee ;
Sibbald, Cathryn ;
Fleming, Patrick J. ;
Piguet, Vincent .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2020, 24 (01) :73-78
[10]   Biologics for pityriasis rubra pilaris treatment: A review of the literature [J].
Napolitano, Monica ;
Abeni, Damiano ;
Didona, Biagio .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) :353-+